Urinary Incontinence Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Urinary Incontinence clinical trial market research report provides an overview of the Urinary Incontinence clinical trials scenario. The report provides top-line data relating to the clinical trials on Urinary Incontinence. The Urinary Incontinence, 2022 report includes an overview of trial numbers and their average enrollment in top countries conducted globally. The clinical trials report also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.
Regional and Country-Wise Outlook of the Urinary Incontinence Clinical Trials Market
Most clinical trials for Urinary Incontinence were conducted in North America, followed by Europe, Asia-Pacific, the Middle East, and Africa, and South and Central America.
In a country-wise analysis, the US has the highest number of Urinary Incontinence clinical trials as of August 2022, followed by the UK, China, Canada, Germany, Japan, France, Czech Republic, the Netherlands, and Iran. The Czech Republic has the highest average patient enrollment of Urinary Incontinence clinical trials.
Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Canada has the highest proportion of Urinary Incontinence to Genito Urinary System and Sex Hormones clinical trials as of August 2022. Additionally, out of all the clinical trials conducted on Urinary Incontinence in the G7 countries, the majority were in the US.
Likewise, among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of Urinary Incontinence to Genito Urinary System and Sex Hormones clinical trials as of August 2022. Moreover, among the E7 countries, most clinical trials conducted on Urinary Incontinence were in China.
Urinary Incontinence Clinical Trials Market Analysis, By Regions
For more regional insights of the Urinary Incontinence Clinical Trials Market , download a free report sample
Urinary Incontinence Clinical Trials Market Segmentation by Sponsor Types
The sponsor types in the Urinary Incontinence clinical trials market are company, institution, and government. More than half of the clinical trials have been sponsored by company.
Urinary Incontinence Clinical Trials Market Analysis, by Sponsor Types
For more insights on Urinary Incontinence Clinical Trials Market sponsor types, download a free report sample
Competitive Landscape
The leading companies in the Urinary Incontinence clinical trials market are Astellas Pharma Inc, AbbVie Inc, Eli Lilly and Co, Pfizer Inc, C. H. Boehringer Sohn AG & Co KG, Sumitovant Biopharma, Inc., Viatris Inc, APOGEPHA Arzneimittel GmbH, Cook Group Inc, and GSK plc. Astellas Pharma Inc has conducted highest number of Urinary Incontinence clinical trials.
Urinary Incontinence Clinical Trials Market Analysis, by Leading Companies
To know more about the leading companies in the Urinary Incontinence Clinical Trials Market, download a free report sample
Urinary Incontinence Clinical Trials Market Report Overview
Key Regions | North America, Europe, Asia Pacific, the Middle East, and Africa, and South and Central America |
Key Countries | The US, the UK, China, Canada, Germany, Japan, France, Czech Republic, the Netherlands, and Iran |
Key Sponsor Types | Company, Institution, and Government |
Leading Companies | Astellas Pharma Inc, AbbVie Inc, Eli Lilly and Co, Pfizer Inc, C. H. Boehringer Sohn AG & Co KG, Sumitovant Biopharma, Inc., Viatris Inc, APOGEPHA Arzneimittel GmbH, Cook Group Inc, and GSK plc |
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
AbbVie Inc
Eli Lilly and Co
Pfizer Inc
C. H. Boehringer Sohn AG & Co KG
Sumitovant Biopharma, Inc.
Viatris Inc
APOGEPHA Arzneimittel GmbH
Cook Group Inc
GSK plc
Table of Contents
Frequently asked questions
-
Which are the key regions in the Urinary Incontinence clinical trials market?
The key regions in the Urinary Incontinence clinical trials market are North America, Europe, Asia Pacific, the Middle East, and Africa, and South and Central America.
-
Which are the key countries in the Urinary Incontinence clinical trials market?
The key countries in the Urinary Incontinence clinical trials market are the US, the UK, China, Canada, Germany, Japan, France, Czech Republic, the Netherlands, and Iran.
-
What are the key sponsor types in the Urinary Incontinence clinical trials market?
The key sponsor types in the Urinary Incontinence clinical trials market are company, institution, and government.
-
Which are the leading companies in the Urinary Incontinence clinical trials market?
The leading companies in the Urinary Incontinence clinical trials market are Astellas Pharma Inc, AbbVie Inc, Eli Lilly and Co, Pfizer Inc, C. H. Boehringer Sohn AG & Co KG, Sumitovant Biopharma, Inc., Viatris Inc, APOGEPHA Arzneimittel GmbH, Cook Group Inc, and GSK plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Genito Urinary System And Sex Hormones reports

